Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma
Interventions: PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Celecoxib|PROCEDURE: Computed Tomography|BIOLOGICAL: Interferon Alpha-2|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|DRUG: Rintatolimod
Sponsor: Roswell Park Cancer Institute
Collaborators: National Cancer Institute (NCI)